Boston Scientific has launched its Interlock-35 Fibered IDC Occlusion System in the U.S. and Europe. Earlier this year, the system received clearance from the FDA and CE Mark approval for obstructing or reducing blood flow in the peripheral vasculature during embolization procedures.
The Interlock-35 System consists of a 0.035" detachable coil with an interlocking connection between the coil and delivery wire designed to offer placement control, including the ability to advance, retract and reposition the coil before final deployment in the vessel. The coil is engineered to be detached by simply pushing the detachment zone beyond the distal end of the 5F delivery catheter. The platinum coil is constructed with a network of synthetic fibers, designed to offer thrombogenicity (blockage of blood flow) and rapid stasis.
The Interlock-35 Fibered IDC Occlusion System is available in 31 configurations that include coil lengths from 4cm to 40cm, diameters from 3mm to 20mm, and three distinct shapes (cube, 2D helical and diamond) to offer physicians greater flexibility to treat diverse vessel anatomy. When combined with Boston Scientific's 0.018" Interlock Fibered IDC Coils, the Interlock Coil portfolio provides 50 different coils to optimize peripheral embolization procedures.